Prelude Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $592K | Sell |
2,015
-5,738
| -74% | -$1.63M | 0.04% | 464 |
|
|
2026
Q1 | $2.16M | Buy |
7,753
+4,289
| +124% | +$1.24M | 0.17% | 156 |
|
|
2025
Q4 | $1.05M | Sell |
3,464
-13,269
| -79% | -$4.14M | 0.08% | 287 |
|
|
2025
Q3 | $4.69M | Sell |
16,733
-12,534
| -43% | -$3.41M | 0.37% | 47 |
|
|
2025
Q2 | $7.06M | Sell |
29,267
-870
| -3% | -$206K | 0.69% | 20 |
|
|
2025
Q1 | $7.34M | Buy |
30,137
+22,029
| +272% | +$6.63M | 0.56% | 26 |
|
|
2024
Q4 | $2.66M | Sell |
8,108
-1,117
| -12% | -$379K | 0.17% | 127 |
|
|
2024
Q3 | $3.09M | Sell |
9,225
-12,800
| -58% | -$4.07M | 0.19% | 134 |
|
|
2024
Q2 | $6.02M | Sell |
22,025
-31,498
| -59% | -$9.16M | 0.42% | 45 |
|
|
2024
Q1 | $18.5M | Buy |
53,523
+3,974
| +8% | +$1.31M | 0.97% | 4 |
|
|
2023
Q4 | $16M | Buy |
49,549
+8,794
| +22% | +$2.76M | 1.06% | 5 |
|
|
2023
Q3 | $14.6M | Buy |
40,755
+16,762
| +70% | +$6.47M | 0.95% | 11 |
|
|
2023
Q2 | $9.1M | Buy |
23,993
+9,477
| +65% | +$3.86M | 0.59% | 20 |
|
|
2023
Q1 | $6.95M | Buy |
14,516
+486
| +3% | +$228K | 0.42% | 33 |
|
|
2022
Q4 | $5.9M | Buy |
14,030
+9,830
| +234% | +$3.97M | 0.31% | 60 |
|
|
2022
Q3 | $1.75M | Buy |
4,200
+786
| +23% | +$392K | 0.06% | 265 |
|
|
2022
Q2 | $1.69M | Buy |
+3,414
| New | +$1.78M | 0.05% | 353 |
|
|
2021
Q2 | – | Sell |
-529
| Closed | -$302K | – | 1654 |
|
|
2021
Q1 | $302K | Buy |
+529
| New | +$313K | 0.01% | 1142 |
|
|
2020
Q3 | – | Sell |
-176
| Closed | -$79K | – | 1841 |
|
|
2020
Q2 | $79K | Buy |
176
+13
| +8% | +$5.74K | ﹤0.01% | 1022 |
|
|
2020
Q1 | $57K | Sell |
163
-243
| -60% | -$89.3K | ﹤0.01% | 720 |
|
|
2019
Q4 | $150K | Buy |
+406
| New | +$143K | 0.01% | 943 |
|
|
2019
Q1 | – | Sell |
-1,040
| Closed | -$242K | – | 1763 |
|
|
2018
Q4 | $242K | Buy |
1,040
+816
| +364% | +$219K | 0.02% | 670 |
|
|
2018
Q3 | $70K | Sell |
224
-2,829
| -93% | -$878K | ﹤0.01% | 1048 |
|
|
2018
Q2 | $881K | Buy |
3,053
+670
| +28% | +$185K | 0.06% | 365 |
|
|
2018
Q1 | $596K | Sell |
2,383
-4,839
| -67% | -$1.23M | 0.04% | 397 |
|
|
2017
Q4 | $1.72M | Sell |
7,222
-3,113
| -30% | -$754K | 0.14% | 152 |
|
|
2017
Q3 | $2.3M | Sell |
10,335
-561
| -5% | -$126K | 0.21% | 106 |
|
|
2017
Q2 | $2.47M | Buy |
10,896
+288
| +3% | +$62.8K | 0.23% | 91 |
|
|
2017
Q1 | $2.12M | Buy |
10,608
+3,421
| +48% | +$659K | 0.2% | 119 |
|
|
2016
Q4 | $1.31M | Sell |
7,187
-3,665
| -34% | -$625K | 0.16% | 164 |
|
|
2016
Q3 | $1.78M | Buy |
10,852
+10,628
| +4,745% | +$1.61M | 0.19% | 121 |
|
|
2016
Q2 | $32K | Sell |
224
-263
| -54% | -$37.5K | ﹤0.01% | 1146 |
|
|
2016
Q1 | $67K | Buy |
+487
| New | +$63.9K | 0.01% | 883 |
|
|
2015
Q2 | – | Sell |
-526
| Closed | -$71K | – | 1708 |
|
|
2015
Q1 | $71K | Buy |
+526
| New | +$65.2K | 0.01% | 1157 |
|
|
2014
Q3 | – | Sell |
-391
| Closed | -$47K | – | 1866 |
|
|
2014
Q2 | $47K | Buy |
391
+181
| +86% | +$22.1K | 0.01% | 1377 |
|
|
2014
Q1 | $27K | Sell |
210
-20
| -9% | -$2.56K | ﹤0.01% | 1607 |
|
|
2013
Q4 | $28K | Buy |
230
+70
| +44% | +$8.53K | ﹤0.01% | 1288 |
|
|
2013
Q3 | $19K | Buy |
+160
| New | +$18.9K | ﹤0.01% | 1218 |
|
Other funds holding BIO
AI
Prelude Capital Management's BIO Position: Q2 2026 in Review
Prelude Capital Management reduced its Bio-Rad Laboratories Class A (BIO) stake by 74% in Q2 2026, selling an estimated $1.63M and leaving 2,015 shares worth $592K. The position accounts for 0.04% of the portfolio, ranked #464.
Prelude Capital Management first reported a position in BIO in Q3 2013 and has held it in 38 quarters since. The position peaked at $18.5M in Q1 2024. 397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.
- Prelude Capital Management held 2,015 shares of Bio-Rad Laboratories Class A worth $592K as of Q2 2026.
- Prelude Capital Management sold 5,738 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $1.63M.
- Bio-Rad Laboratories Class A made up 0.04% of Prelude Capital Management's portfolio in Q2 2026, its #464 holding.
- Prelude Capital Management first reported a position in Bio-Rad Laboratories Class A in Q3 2013 and has held it in 38 quarters since.
- Prelude Capital Management's Bio-Rad Laboratories Class A position peaked at $18.5M in Q1 2024.
- 397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.
Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.